| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/16/2004 | EP1014961B1 Treatment of migraine headache using metoclopramide and an nsaid |
| 06/16/2004 | EP0977725B1 New fatty acid derivatives |
| 06/16/2004 | EP0977554B1 Confectionery compositions |
| 06/16/2004 | EP0923399B1 Kit of parts comprising three vials for embolizing vascular sites with an embolizing composition comprising dimethylsulfoxide |
| 06/16/2004 | EP0902777B2 D-mannitol and its preparation |
| 06/16/2004 | EP0788308B1 Polymeric wound healing accelerators |
| 06/16/2004 | EP0760689B1 Method of manufacturing and storing solutions |
| 06/16/2004 | CN1505617A Peptides as met-ap2 inhibitors |
| 06/16/2004 | CN1505528A Immunogen comprising ligand bound hiv envelpe protein |
| 06/16/2004 | CN1505524A Immunopotentiators |
| 06/16/2004 | CN1505523A Method for producing pellet and tablet |
| 06/16/2004 | CN1505520A Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative |
| 06/16/2004 | CN1505519A Amphotericin B aqueous composition |
| 06/16/2004 | CN1505517A Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis |
| 06/16/2004 | CN1505515A Oral pharmaceutical composition of cefpodoxime proxetil |
| 06/16/2004 | CN1505513A Aqueous cilostazol preparation for injection |
| 06/16/2004 | CN1505512A A stable pharmaceutical formulation comprising torsemide modification II |
| 06/16/2004 | CN1505503A Method for preparing submicron particle suspensions |
| 06/16/2004 | CN1505502A Fibrate-statin combinations with reduced fed-fasted effects |
| 06/16/2004 | CN1504196A Use of glycyrrhizin and its derivatives as mcp-1 production inhibitors |
| 06/16/2004 | CN1504185A 药物组合物 The pharmaceutical composition of |
| 06/16/2004 | CN1153777C Process for preparing a charcoal-GM1 complex |
| 06/16/2004 | CN1153576C Composition and method for treating bladder cancer |
| 06/16/2004 | CN1153571C External therapeutic composition for dermatitis |
| 06/16/2004 | CN1153570C Method and composition of an oral preparation of itraconazole |
| 06/16/2004 | CN1153567C Scale production method of forming microparticles |
| 06/15/2004 | US6750340 Bisphosphonate conjugates and methods of making and using the same |
| 06/15/2004 | US6750331 Has improved texture and high stability and is in the form of foaming chewable tablets |
| 06/15/2004 | US6750329 Antibody delivery system for biological response modifiers |
| 06/15/2004 | US6750249 Gradually release esculetin or its derivative in a controlled manner over a long period of time |
| 06/15/2004 | US6750238 Aralkyl ester soft drugs |
| 06/15/2004 | US6750237 Pharmaceutical formulations containing zolmitriptan |
| 06/15/2004 | US6750210 Formulation containing novel anti-inflammatory androstane derivative |
| 06/15/2004 | US6750058 For treatment and prevention of human and animal diseases; in particular capable of dispensing to suitable target cells nucleic sequences, proteins, peptides and chemical substances via transfection |
| 06/15/2004 | US6749869 Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection |
| 06/15/2004 | US6749868 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| 06/15/2004 | US6749865 Modification of biopolymers for improved drug delivery |
| 06/15/2004 | US6749864 Stabilized pharmaceutical composition |
| 06/15/2004 | US6749853 Combined methods and compositions for coagulation and tumor treatment |
| 06/15/2004 | US6749851 Applying radiation |
| 06/15/2004 | US6749845 Modulated release particles for lung delivery |
| 06/15/2004 | US6748950 Compositions and medical procedure to treat snoring |
| 06/15/2004 | CA2329800C Protein formulations |
| 06/15/2004 | CA2088334C Fast dissolving tablet and its production |
| 06/10/2004 | WO2004049358A2 Multifunctional particulate material, fluid, and composition |
| 06/10/2004 | WO2004048406A1 Nucleic acid comprising a sequence encoding a modified glutenin polypeptide |
| 06/10/2004 | WO2004048287A1 Hardening bone compensate and remedy for skin defect using calcium phosphate sustainedly releasing zinc |
| 06/10/2004 | WO2004047881A1 Calcium phosphate carrying protein, process for producing the same and sustained release protein preparation, artificial bone and tissue enginerring scaffold using the same |
| 06/10/2004 | WO2004047871A2 Modified naturetic compounds, conjugates, and uses thereof |
| 06/10/2004 | WO2004047870A1 Nanoparticle conjugates and method of production thereof |
| 06/10/2004 | WO2004047869A1 Dendrimer conjugates for selective of protein aggregates |
| 06/10/2004 | WO2004047858A1 Novel use of erythropoietin in heart diseases |
| 06/10/2004 | WO2004047846A1 Oil/glycyrrhizin-containing surfactant phase type gel composition |
| 06/10/2004 | WO2004047839A1 High concentration formulations of opioids and opioid derivatives |
| 06/10/2004 | WO2004047820A1 Warm poultice |
| 06/10/2004 | WO2004047812A1 Hollow nanoparticles of protein and drug using the same |
| 06/10/2004 | WO2004047811A1 Controlled release formulation of tamsulosin or pharmaceutically acceptable salts thereof for treatment of the signs and symptoms of benign prostatic hyperplasia |
| 06/10/2004 | WO2004047805A1 Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof |
| 06/10/2004 | WO2004047804A1 Emulsion of perfluororganic compounds exhibiting gas-transport properties, a surface-active agent for said emulsion and method for the production thereof. |
| 06/10/2004 | WO2004047803A1 An injection of animal remedy including closantel or closantel sodium |
| 06/10/2004 | WO2004047799A2 Pellets containing non-aqueous fluids and the process for their preparation |
| 06/10/2004 | WO2004047795A2 Cutaneous application of flupirtine |
| 06/10/2004 | WO2004047791A2 Emulsive water-soluble concentrates |
| 06/10/2004 | WO2004047790A2 Self-forming phospholipidic gels |
| 06/10/2004 | WO2004047778A1 Materials and methods for preventing and treating microbe-mediated epithelial disorders |
| 06/10/2004 | WO2004047771A2 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof |
| 06/10/2004 | WO2004047768A2 Buoyant polymer particles delivering therapeutic agents |
| 06/10/2004 | WO2004047735A2 Broad spectrum anti-viral therapeutics and prophylaxis |
| 06/10/2004 | WO2004047729A2 Composition for the prevention and treatment of inflammation of the ear |
| 06/10/2004 | WO2004047713A2 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 06/10/2004 | WO2004047564A1 Novel pharmaceutical compositions in particular for preventing cardiovascular pathologies |
| 06/10/2004 | WO2004047559A1 Method of inhibiting acrylamide formation and use thereof |
| 06/10/2004 | WO2004035093A3 Polymeric materials for site specific delivery to the body |
| 06/10/2004 | WO2004033484A3 Use of stable glutamine derivatives to improve drug absorption |
| 06/10/2004 | WO2004027385A3 Engineering of material surfaces |
| 06/10/2004 | WO2004026262A3 Abuse-resistant pharmaceutical compositions |
| 06/10/2004 | WO2004020468A3 Interferon beta-like molecules for treatment of cancer |
| 06/10/2004 | WO2004017810A3 Tumor specific oligosaccharide epitopes and use thereof |
| 06/10/2004 | WO2004012680A3 Lipid-drug complexes in reversed liquid and liquid crystalline phases |
| 06/10/2004 | WO2004010957A3 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 06/10/2004 | WO2004009666A3 Dendrimers as molecular translocators |
| 06/10/2004 | WO2004006801A3 Treatment for dry eye syndrome |
| 06/10/2004 | WO2004003145A3 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/10/2004 | WO2004002447A3 Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton |
| 06/10/2004 | WO2003106592A3 Ether alcohols used as solvents and emulsifiers and dispersions containing said ether alcohols |
| 06/10/2004 | WO2003087323A3 Biologic modulations with nanoparticles |
| 06/10/2004 | WO2003087307A3 Use of interleukin-19 to treat cervical cancer |
| 06/10/2004 | WO2003084469A3 Tissue-specific endothelial membrane proteins |
| 06/10/2004 | WO2003070970A3 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 06/10/2004 | WO2003035080A3 A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 06/10/2004 | WO2003026689A8 Autologous growth factor cocktail composition, method of production and use |
| 06/10/2004 | WO2003024433A3 Compositions for treatment of common cold, comprising ipratropium and xylometazoline |
| 06/10/2004 | WO2003013617A3 Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in nmr diagnosis and radiodiagnosis and radiotherapy |
| 06/10/2004 | WO2002053091A3 Medicinal combination of a biguanine (metformin) and arginine |
| 06/10/2004 | WO2002038168A3 Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases |
| 06/10/2004 | US20040110935 Universal carrier for targeting molecules to Gb3 receptor expressing cells |
| 06/10/2004 | US20040110929 compounds that bind to and inhibit the activity of tissue factor (TF) and mediate a cytolytic immune response; used in treatment of or prophylaxis of diseases or disorders related to pathophysiological TF activity including cancer, inflammation etc |
| 06/10/2004 | US20040110928 Peptide conjugates for drug delivery |
| 06/10/2004 | US20040110898 Method for producing capsules containing an active ingredient and having an ultra-thin coating |
| 06/10/2004 | US20040110843 in a patient suffering from a co-morbid condition comprising placing in the fossa navicularis a semi-solid composition comprising a vasoactive prostaglandin and a penetration enhancer; co-morbid condition is diabetes mellitus, hypertension, etc |